The purpose of this study is to determine the appropriate dose of the investigational drug, irinotecan (CPT-11) when given on a once every-three-week schedule to patients with advanced solid tumor cancers. The side effects experienced by patients and the rate at which the body removes the drug from blood will be evaluated.
Showing the most recent 10 out of 1267 publications